Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 5/20 | 0.43 |
| ▸ | CDK2 | P24941 | 5/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13358975 | 0.90 | PIK3CA (0.45) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL3232125 | 0.88 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL3240860 | 0.88 | PIK3CA (0.45) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL3668513 | 0.88 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL3665106 | 0.88 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL3232956 | 0.87 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL3661249 | 0.83 | KDM4E (0.49) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL3661132 | 0.83 | PIK3CA (0.40) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL29011712 | 0.81 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH | |
| SCHEMBL3235686 | 0.80 | PIK3CA (0.36) | PIK3CAPIK3CDPIK3CBPIK3CGFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-1622897-B1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | PIK3CA 1/4885PIK3CD 4/4885PIK3CB 8/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CB 4/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.